Convergent transcriptomic and genomic evidence supporting a dysregulation of CXCL16 and CCL5 in Alzheimer’s disease

Table 3 Summary results of bi-direction MR estimates for causal effect between chemokines and Alzheimer’s disease

Exposure	Exposure ID	Outcome	Outcome ID	Nsnp	β	SE	P	OR	95% CI
CCL5	prot-a-409	Alzheimer's disease	ieu-b-2	29	− 0.0667	0.0240	0.0055	0.94	0.89–0.98
CXCL1	prot-b-16	Alzheimer's disease	ieu-b-2	8	− 0.0251	0.0353	0.4773	0.98	0.91–1.05
CXCL16	prot-a-745	Alzheimer's disease	ieu-b-2	27	− 0.0050	0.0246	0.8404	1.00	0.95–1.04
Alzheimer’s disease	ieu-b-2	CCL5	prot-a-409	50	0.0078	0.0290	0.7864	1.01	0.95–1.07
Alzheimer’s disease	ieu-b-2	CXCL1	Prot-b-16	32	0.0016	0.0380	0.9657	1.00	0.93–1.08
Alzheimer’s disease	ieu-b-2	CXCL16	prot-a-745	50	− 0.0404	0.0290	0.1636	0.96	0.91–1.02

Nsnp Number of SNPs used as instrumental variables with GWAS p < 1.0 × 10⁻⁵
β The effect size of exposure on outcome
SE Standard error of β
P P value of the causal effect inference by inverse-variance weighted (IVW) model
OR Odds ratio of the causal effect, 95% CI 95% confidence interval of OR

ISSN: 1758-9193